Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Moll

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
Frontiers in Public Health|June 16, 2023
Comparison of treatment costs for primary localized prostate cancer in Austria and Vienna: an economic analysisMatthias Moll, Gregor Goldner
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|June 21, 2023
Assessing the toxicity after moderately hypofractionated prostate and whole pelvis radiotherapy compared to conventional fractionationMatthias Moll, Gregor Goldner
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|January 27, 2021
Biochemical control after adjuvant radiation therapy for prostate cancer: a unicentric, retrospective analysisAlexandru-Teodor Zaharie, Matthias Moll, Gregor Goldner
Radiology and Oncology|May 3, 2022
Advancements in the radiooncological treatment of high-risk prostate cancer: a quarter century of achievementsMatthias Moll, Harald Herrmann, Alexandru Zaharie, et al.
European Journal of Biochemistry|August 16, 2002
ISC1-encoded inositol phosphosphingolipid phospholipase C is involved in Na+/Li+ halotolerance of Saccharomyces cerevisiaeChristian Betz, Dirk Zajonc, Matthias Moll, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|August 11, 2022
Clinical outcome in metastatic prostate cancer after primary radiotherapyMatthias Moll, Harald Herrmann, Alexandru Zaharie, et al.
Current Opinion in Urology|August 6, 2025
Carbon ion radiotherapy as a dose escalation tool in the treatment of primary high-risk prostate cancerMatthias Moll, Piero Fossati, Carola Lütgendorf-Caucig, et al.
Radiology and Oncology|January 18, 2023
Effects of gold fiducial marker implantation on tumor control and toxicity in external beam radiotherapy of prostate cancerMatthias Moll, Magdalena Weiß, Vladimir Stanisav, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|July 10, 2020
Treatment of low-risk prostate cancer: a retrospective study with 477 patients comparing external beam radiotherapy and I-125 seeds brachytherapy in terms of biochemical control and late side effectsMatthias Moll, Christopher Paschen, Alexandru Zaharie, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|August 5, 2021
Comparison of EBRT and I-125 seed brachytherapy concerning outcome in intermediate-risk prostate cancerMatthias Moll, Andreas Renner, Christian Kirisits, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Frontiers in Public Health|June 16, 2023
Comparison of treatment costs for primary localized prostate cancer in Austria and Vienna: an economic analysisMatthias Moll, Gregor Goldner
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|June 21, 2023
Assessing the toxicity after moderately hypofractionated prostate and whole pelvis radiotherapy compared to conventional fractionationMatthias Moll, Gregor Goldner
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|January 27, 2021
Biochemical control after adjuvant radiation therapy for prostate cancer: a unicentric, retrospective analysisAlexandru-Teodor Zaharie, Matthias Moll, Gregor Goldner
Radiology and Oncology|May 3, 2022
Advancements in the radiooncological treatment of high-risk prostate cancer: a quarter century of achievementsMatthias Moll, Harald Herrmann, Alexandru Zaharie, et al.
European Journal of Biochemistry|August 16, 2002
ISC1-encoded inositol phosphosphingolipid phospholipase C is involved in Na+/Li+ halotolerance of Saccharomyces cerevisiaeChristian Betz, Dirk Zajonc, Matthias Moll, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|August 11, 2022
Clinical outcome in metastatic prostate cancer after primary radiotherapyMatthias Moll, Harald Herrmann, Alexandru Zaharie, et al.
Current Opinion in Urology|August 6, 2025
Carbon ion radiotherapy as a dose escalation tool in the treatment of primary high-risk prostate cancerMatthias Moll, Piero Fossati, Carola Lütgendorf-Caucig, et al.
Radiology and Oncology|January 18, 2023
Effects of gold fiducial marker implantation on tumor control and toxicity in external beam radiotherapy of prostate cancerMatthias Moll, Magdalena Weiß, Vladimir Stanisav, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|July 10, 2020
Treatment of low-risk prostate cancer: a retrospective study with 477 patients comparing external beam radiotherapy and I-125 seeds brachytherapy in terms of biochemical control and late side effectsMatthias Moll, Christopher Paschen, Alexandru Zaharie, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|August 5, 2021
Comparison of EBRT and I-125 seed brachytherapy concerning outcome in intermediate-risk prostate cancerMatthias Moll, Andreas Renner, Christian Kirisits, et al.
Pageof 3